Coronavirus disease 2019 (COVID-19) pandemic has killed huge populations throughout the world and acts as a high-risk factor for elderly and young immune-suppressed patients. There is a critical need to build up secure, reliable, and efficient drugs against to the
infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Bioactive compounds of
Ashwagandha [Withania somnifera (L.) Dunal] may implicate as herbal medicine for the management and treatment of patients infected by
SARS-CoV-2 infection. The aim of the current work is to update the knowledge of
SARS-CoV-2 infection and information about the implication of various compounds of medicinal plant Withania somnifera with minimum side effects on the patients' organs. The herbal medicine Withania somnifera has an excellent
antiviral activity that could be implicated in the management and treatment of flu and flu-like diseases connected with SARS-CoV-2. The analysis was performed by systematically re-evaluating the published articles related to the
infection of SARS-CoV-2 and the herbal medicine Withania somnifera. In the current review, we have provided the important information and data of various bioactive compounds of Withania somnifera such as
Withanoside V,
Withanone, Somniferine, and some other compounds, which can possibly help in the management and treatment of
SARS-CoV-2 infection. Withania somnifera has proved its potential for maintaining immune homeostasis of the body,
inflammation regulation, pro-inflammatory
cytokines suppression, protection of multiple organs, anti-viral, anti-stress, and
anti-hypertensive properties.
Withanoside V has the potential to inhibit the main
proteases (Mpro) of SARS-CoV-2. At present, synthetic adjuvant
vaccines are used against
COVID-19. Available information showed the
antiviral activity in
Withanoside V of Withania somnifera, which may explore as herbal medicine against to
SARS-CoV-2 infection after standardization of parameters of
drug development and formulation in near future.